Literature DB >> 29949664

NR4A1 Regulates Motility of Osteoclast Precursors and Serves as Target for the Modulation of Systemic Bone Turnover.

Carina Scholtysek1,2, Natacha Ipseiz3, Christina Böhm1,2, Brenda Krishnacoumar1,2, Martin Stenzel1,2, Tina Czerwinski4, Katrin Palumbo-Zerr1,2, Tobias Rothe1,2, Daniela Weidner1,2, Alexandra Klej1,2, Cornelia Stoll1,2, Jörg Distler1, Jan Tuckermann5, Martin Herrmann1, Ben Fabry4, Wolfgang H Goldmann4, Georg Schett1, Gerhard Krönke1,2.   

Abstract

NR4A1 (Nur77 or NGFI-B), an orphan member of the nuclear receptor superfamily, has been identified as a key regulator of the differentiation and function of myeloid, lymphoid, and mesenchymal cells. The detailed role of NR4A1 in bone biology is incompletely understood. Here, we report a role for NR4A1 as novel factor controlling the migration and recruitment of osteoclast precursors during bone remodeling. Myeloid-specific but not osteoblast-specific deletion of NR4A1 resulted in osteopenia due to an increase in the number of bone-lining osteoclasts. Although NR4A1-deficient osteoclast precursors displayed a regular differentiation into mature osteoclasts, they showed a hyper-motile phenotype that was largely dependent on increased osteopontin expression, suggesting that expression of NR4A1 negatively controlled osteopontin-mediated recruitment of osteoclast precursors to the trabecular bone. Pharmacological activation of NR4A1, in turn, inhibited osteopontin expression and osteopontin-dependent migration of osteoclast precursors resulted in reduced abundance of bone-resorbing osteoclasts in vivo as well as in an ameliorated bone loss after ovariectomy in mice. This study identifies NR4A1 as a crucial player in the regulation of osteoclast biology and bone remodeling and highlights this nuclear receptor as a promising target for therapeutic intervention during the treatment of osteoporosis.
© 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Entities:  

Keywords:  CELL MIGRATION; NUCLEAR RECEPTORS; OSTEOCLASTS; OSTEOIMMUNOLOGY; OSTEOPOROSIS

Mesh:

Substances:

Year:  2018        PMID: 29949664     DOI: 10.1002/jbmr.3533

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  6 in total

1.  Characterization and regulation of osteoclast precursors following chronic Porphyromonas gingivalis infection.

Authors:  Yanfang Zhao; Zhaofei Li; Lingkai Su; Andre Ballesteros-Tato; Jannet Katz; Suzanne M Michalek; Xu Feng; Ping Zhang
Journal:  J Leukoc Biol       Date:  2020-08-17       Impact factor: 4.962

Review 2.  Bone remodeling: an operational process ensuring survival and bone mechanical competence.

Authors:  Simona Bolamperti; Isabella Villa; Alessandro Rubinacci
Journal:  Bone Res       Date:  2022-07-18       Impact factor: 13.362

3.  Contribution of Glucosylceramide Synthase to the Proliferation of Mouse Osteoblasts.

Authors:  Yoshitaka Mishima; Kazunori Hamamura; Hanami Kato; Koichi Furukawa; Yuko Tashima; Tetsuya Okajima; Hisataka Kondo; Takuma Sato; Ken Miyazawa; Shigemi Goto; Akifumi Togari
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

4.  Time course of collateral vessel formation after retinal vein occlusion visualized by OCTA and elucidation of factors in their formation.

Authors:  Hajime Takahashi; Kazuki Nakagawa; Haruhiko Yamada; Hidetsugu Mori; Shimpei Oba; Keiko Toyama; Kanji Takahashi
Journal:  Heliyon       Date:  2021-01-05

5.  Nur77 Prevents Osteoporosis by Inhibiting the NF-κB Signalling Pathway and Osteoclast Differentiation.

Authors:  Huanlian Tian; Feng Chen; Yingfang Wang; Yixuan Liu; Guojing Ma; Yuhong Zhao; Yanan Ma; Tingting Tian; Ruze Ma; Yang Yu; Difei Wang
Journal:  J Cell Mol Med       Date:  2022-02-19       Impact factor: 5.310

Review 6.  Updates on Osteoimmunology: What's New on the Cross-Talk Between Bone and Immune System.

Authors:  Marco Ponzetti; Nadia Rucci
Journal:  Front Endocrinol (Lausanne)       Date:  2019-04-18       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.